sar425899 sanofi glp-1 glucagon dual agonist The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Receptor - An Update Receptor occupancy of dual glucagon-like
Description
Petersen N, Reimann F, Bartfeld S, Farin HF, Ringnalda FC, Vries RGJ, et al
Current understanding is largely based on pharmacovigilance data, clinical trial secondary endpoints, case reports, and small observational studies
doi: 10.1016/s0006-8993(97)01057-3
Beam and Hunter Guevara 2023
Evidence from both preclinical and clinical studies supports their antiinflammatory roles in the cardiovascular system, liver, kidneys, and joints
GIP(3-30)NH 2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study
